To provide updated evidence-based recommendations for migraine prevention using pharmacologic treatment with or without cognitive behavioral therapy in the pediatric population.
This article summarizes the findings of a systematic review and practice guideline on the pharmacologic treatment of migraine prevention in children and adolescents. The unabridged practice guideline is available at https://www.aan.com/Guidelines/ home/GetGuidelineContent/978 and includes full details of the methodology used, including the risk of bias assessment for each study, meta-analysis, and confidence in evidence determinations.
This guideline systematically evaluates new evidence to answer the following clinical question: In children and adolescents with migraines, do preventive pharmacologic treatments, with or without cognitive behavioral therapy (CBT), compared with placebo, reduce headache frequency?
Migraine is common in children and adolescents, with a prevalence of 1%-3% in 3-to 7-year-olds, 4%-11% in 7-to 11-yearolds, and 8%-23% by age 15 years. 1 Diagnosis of primary headache disorders is based on clinical criteria by the International Classification of Headache Disorders, 3rd edition, by the International Headache Society. 2 Most children benefit from acute migraine treatments along with behavioral and lifestyle changes for headache prevention and do not require additional pharmacologic or biobehavioral preventive treatment. 3 Additional migraine prevention should be considered when headaches occur with sufficient frequency and severity and result in migraine-related disability. The Pediatric Migraine Disability Assessment (PedMIDAS) is a 6-question, self-administered scale developed and validated in children and adolescents to measure functional impact of pediatric migraine during a 3-month period. 4 
Description of analytic process
This guideline was developed according to the process described in the 2011 American Academy of Neurology (AAN) guideline development process manual as amended 5 and is in compliance with the National Academy of Medicine (formerly Institute of Medicine) Standards for Systematic Reviews. 6 A multidisciplinary author panel, consisting of headache experts, child neurologists, clinical psychologists, methodologists, and patients, was assembled by the Guideline Development, Dissemination, and Implementation Subcommittee of the AAN to write this guideline. This author panel was solely responsible for the final decisions about the design, analysis, and reporting of the guideline. The study protocol was posted for public comment according to the 2011 process manual as amended.
The authors included randomized clinical trials of migraine prevention in children aged 3-18 years and considered studies published in English and in other languages. The headache disorders in these studies were classified according to either the International Classification of Headache Disorders, 2nd edition, 7 or the International Classification of Headache Disorders, 3rd edition (beta version). 8 Special populations included sexually active adolescents who were of childbearing age. Patients with episodic syndromes that may be associated with migraine, including cyclic vomiting, abdominal migraine, benign paroxysmal vertigo, and benign paroxysmal torticollis, were excluded. The systematic review included all pharmacologic interventions for the preventive treatment of migraine as well as the use of CBT in combination with pharmacologic therapy, with placebo used as the comparator. The outcome measures included change in headache frequency (defined as the reduction in number of migraine days per month, reduction of number of headache days per month, or 50% reduction in these frequencies), headache severity (defined by visual analog scale or numerical rating scale), and associated disability (PedMIDAS).
This guideline is an update of the previous guideline published in 2004 on the treatment of migraine in children and adolescents. The authors performed an initial English language literature search from December 1, 2003 , to February 15, 2015 , of the following databases: MEDLINE, Cochran, CINAHL, EMBASE, CDSR, DARE, CENTRAL, and an updated literature search of the same databases from January 1, 2015, to August 25, 2017. The search was conducted to find articles on both acute and preventive treatment of migraine in children and adolescents, although only trials evaluating preventive therapies were included in this systematic review. Two authors independently reviewed all abstracts and full-text articles for relevance. Articles were included if (1) 90% of participants were aged 3-18 years, (2) participants had a diagnosis of migraine, (3) the article included at least 20 participants, and (4) comparison was with placebo. The initial literature search included both pharmacologic and nonpharmacologic interventions, but due to a large number of included studies, the inclusion criteria were narrowed to only prescription pharmacologic intervention alone or in combination with CBT. Nonpharmacologic interventions, such as behavioral interventions alone or nutraceuticals, are not addressed by this guideline. Differences were reconciled by discussion; where disagreements arose, a methodologist on the panel (D.G.) adjudicated. In addition, all Class I and II studies [9] [10] [11] [12] included in the 2004 guideline were also included. Following full-text screening, all included articles were reviewed independently by 2 authors who extracted key data from each article and determined the article's class using a standardized data extraction form that was developed for Glossary AAN = American Academy of Neurology; CBT = cognitive behavioral therapy; CI = confidence interval; DVPX ER = extendedrelease divalproex sodium; FDA = Food and Drug Administration; PedMIDAS = Pediatric Migraine Disability Assessment; RR = risk ratio; SMD = standardized mean differences. each clinical question by the AAN methodologists (T.P., D.G.) with input from the author panel.
The author panel reviewed the results of a comprehensive literature search (1,994 total abstracts) and identified published studies relevant to the clinical questions (the full texts of 313 articles were reviewed), which were then classified according to the AAN's 2011 evidence-based methodology, as amended. From this search and classification strategy, 11 articles ranked as Class I, II, or III were included. In addition, the 7 prevention studies from the 2004 guideline that were previously rated as Class I or II were reclassified using the 2011 process manual, as amended, and 4 rated as Class III or higher were included in the current review (figure). All 4 articles were downgraded to Class II or III when graded according to the 2011 process as amended, typically because of failure to specify concealed allocation and to state a primary outcome. [13] [14] [15] [16] [17] The author panel based the strength of the recommendations on the grading of evidence, with consideration of costs, risks, and feasibility as well as the AAN's modifications to the Grade of Recommendations, Assessment, Development, and Evaluation. Risk ratios (RR) and standardized mean differences (SMD) and the 95% confidence interval (CI) for the outcomes of interest were calculated. For the headache responder rate outcome (proportion of participants with a 50% reduction or greater in headache frequency from baseline), we calculated the RR. We prespecified a minimal clinically important difference of 1.25 between treatment and placebo; an RR less than 1.10 was determined to be clinically unimportant. For continuous headache frequency outcomes, including the number of headache days, the number of migraine days, and migraine-related disability at endpoint, we examined the SMD. We prespecified a minimal clinically important difference in the SMD of 0.20; an SMD less than 0.1 was determined to be clinically unimportant. 18 The panel formulated practice recommendations based on the strength of evidence and other factors, including axiomatic principles of care, the magnitude of anticipated health benefits relative to harms, financial burden, availability of interventions, and patient preferences. The panel assigned levels of obligation (A, B, C, U, R) to the recommendations using a modified Delphi process.
Analysis of evidence
Conclusions to the analysis of evidence are listed as follows. These conclusions are also summarized in the table.
In children and adolescents with migraine, do preventive pharmacologic treatments, compared with placebo, reduce headache frequency?
Antiepileptic drugs Topiramate
Children and adolescents with migraine receiving topiramate are probably more likely than those receiving placebo to have a decrease in the frequency of migraine or headache days (moderate confidence in the evidence, 4 Class I studies [19] [20] [21] [22] ; random effect model SMD 0.391; 95% CI 0.127-0.655; confidence in the evidence downgraded due to imprecision). There is insufficient evidence to determine whether children with migraine receiving topiramate are more or less likely than those receiving placebo to have at least a 50% reduction in headache frequency (very low confidence in the evidence; RR 1.330 [95% CI 0.933-1.894]; confidence in the evidence downgraded due to imprecision). Children with migraine receiving topiramate are possibly no more likely than those receiving placebo to have a decrease in migraine-related disability (low confidence in the evidence, 2 Class I studies 20, 22 ; SMD 0.538 [95% CI −0.097 to 1.174]; confidence in the evidence downgraded due to imprecision).
Extended-release divalproex sodium (DVPX ER)
There is insufficient evidence to determine whether children with migraine who are receiving DVPX ER (250, 500, or 1,000 mg/d) are more or less likely than those receiving placebo to have a reduction in headache frequency (very low confidence in evidence, 1 Class II study 23 downgraded for imprecision). There is insufficient evidence to determine whether children with migraine who are receiving DVPX ER are more or less likely than those receiving placebo to have at least a 50% reduction in headache frequency (very low confidence in the evidence, 1 Class II study downgraded for imprecision; RR 0.92 [95% CI 0.70-1.24]).
Antidepressant drugs Amitriptyline
There is insufficient evidence to determine whether children with migraine receiving amitriptyline are more or less likely than those receiving placebo to have a decrease in migraine attacks (SMD 0.11 [95% CI −0.18 to 0.41]), to have at least a 50% reduction in headache frequency (RR 0.86 [95% CI 0.68-1.13]), or to have a reduction in migraine-related disability (SMD 0.03 [95% CI −0.27 to 0.32]) (very low confidence in the evidence, 1 Class I study, 20 confidence in the evidence downgraded for imprecision).
β-Blockers Propranolol
Children with migraine receiving propranolol are possibly more likely than those receiving placebo to have at least a 50% reduction in headache attacks (low confidence in the evidence, 1 Class III study 24 ; RR 5.20 [95% CI 1.59-17.00]; confidence in evidence upgraded due to magnitude of effect).
Calcium channel blockers Flunarizine
There is insufficient evidence to determine whether children with migraine receiving flunarizine are more or less likely than those receiving placebo to have a decrease in migraine attacks (very low confidence in evidence, 1 Class III study 25 ). Flunarizine is not available in the United States but is available in Canada.
Cinnarizine
Children with migraine receiving cinnarizine are probably more likely than those receiving placebo to have a reduction in headache frequency (moderate confidence in the evidence, 1 Class II study 26 ; SMD 0.83 [95% CI 0.31-1.35]; confidence in the evidence upgraded due to magnitude of effect). Children with migraine receiving cinnarizine are probably more likely than those receiving placebo to have a reduction in headache severity (moderate confidence in the evidence, 1 Class II study; SMD 0.97 [95% CI 0.45-1.50]; confidence in the evidence upgraded due to magnitude of effect). Children with migraine receiving cinnarizine are possibly more likely than those receiving placebo to have at least a 50% reduction in headache frequency (low confidence in the evidence; 1 Class II study; RR 1.92 [95% CI 1.09-3.48]). Cinnarizine is not available in the United States or Canada.
Nimodipine
There is insufficient evidence to determine if children with migraine receiving nimodipine are more or less likely than those receiving placebo to have a decrease in migraine attacks (very low confidence in the evidence, 1 Class III study 27 ).
Neurotoxins OnabotulinumtoxinA
There is insufficient evidence to determine whether adolescents with chronic migraine receiving onabotuli-numtoxinA, 74 units IM, are more or less likely than those receiving placebo to have a reduction in headache frequency (SMD 0.05 [95% CI −0.39 to 0.49]) or to have at least a 50% reduction in frequency of headache days (RR 1.10 [95% CI 0.58-2.09]) (very low confidence in the evidence, 1 Class II study 28 downgraded for imprecision). There is insufficient evidence to determine whether adolescents with chronic migraine receiving onabotulinumtoxinA, 155 units IM, are more or less likely than those receiving placebo to have a reduction in headache frequency (SMD 0.75 [95% CI −0.37 to 0.51]) or to have at least a 50% reduction in frequency of headache days (RR 0.97 [95% CI 0.51-1.89]) (very low confidence in the evidence, 1 Class II study 28 downgraded for imprecision).
In children and adolescents with migraine, do pharmacologic treatments combined with CBT, compared with the same pharmacologic treatments combined with a control intervention, reduce headache frequency? Children and adolescents aged 10-17 years with chronic migraine who receive amitriptyline and CBT are more likely than those who receive amitriptyline and headache education to have a reduction in headache frequency (SMD 0.48 [95% CI 0.14-0.82]; high confidence in the evidence; 1 Class I study, 29 confidence in the evidence upgraded due to magnitude of effect) and to have at least a 50% reduction in headache frequency (RR 1.79 [95% CI 1.27-2.56]; high confidence in evidence, 1 Class I study, confidence in evidence upgraded due to magnitude of effect). Children and adolescents aged 10-17 years with migraine who receive amitriptyline and CBT are probably more likely than those who receive amitriptyline and headache education to have a reduction in headache-related disability (PedMIDAS SMD 
Practice recommendations
Counseling and education for children and adolescents with migraine and their families Recommendation 1 rationale Individuals with a family history of migraine are at higher risk of developing migraine, and female sex is a risk factor of migraine that persists into adulthood. 30 Disease prevention is the cornerstone of medical care. Migraine has multiple behavioral factors that influence headache frequency. Recurrent headache in adolescents is associated with being overweight, caffeine and alcohol use, lack of physical activity, poor sleep habits, and tobacco exposure. 31 Depression is associated with higher headache disability in adolescents. 32 Weight loss can contribute to headache reduction in children who are overweight. 33 Identification and avoidance of factors that contribute to headache risk can reduce migraine frequency.
Statement 1a
Clinicians should counsel patients and families that lifestyle and behavioral factors may influence headache frequency (Level B).
Statement 1b
Clinicians should educate patients and families to identify and modify migraine contributors that are potentially modifiable (Level B).
Recommendation 2 rationale
In adults with migraine, headache on more than 6 days in a month is a risk factor for progression to chronic migraine, with medication overuse contributing to this progression. 34 Taking triptans, ergotamines, opioids, and combination analgesics on more than 9 days in a month or taking overthe-counter simple analgesics on more than 14 days in a month can lead to medication overuse headache. (There is no evidence to support the use of opioids in children with migraine. Opioids are included in this rationale to be consistent with the International Classification of Headache Disorders 35 regarding medication overuse.) It has been suggested that clinicians consider preventive treatments in these populations. 36 Although there are no data on this topic in pediatric populations, it is hypothesized that similar relationships between frequent headache, medication overuse, and progression to chronic migraine may occur in children. In clinical trials of pediatric migraine prevention, inclusion criteria for headache frequency were variable and included a minimum of 4 headache days per month with no maximum and 3-4 migraine attacks per month for at least 3 months. In teenagers with migraine, those with a PedMI-DAS score over 30, indicating moderate to severe migrainerelated disability, had a higher risk of mood and anxiety disorders and increased severity and frequency of headache. 37 
Statement 2a
Clinicians should discuss the potential role of preventive treatments in children and adolescents with frequent headache or migraine-related disability or both (Level B).
Statement 2b
Clinicians should discuss the potential role of preventive treatments in children and adolescents with medication overuse (Level B).
Starting preventive treatment Recommendation 3 rationale
The majority of randomized controlled trials that studied the efficacy of preventive medications for pediatric migraine fail to demonstrate superiority to placebo. Pediatric migraine trial results demonstrated a high response to placebo, with 30%-61% of children who received placebo having had a 50% or greater reduction in headache frequency. Children and adolescents with migraine receiving topiramate are probably more likely than those receiving placebo to have a decrease in headache days and migraine attacks; however, there is insufficient evidence to determine whether children with migraine who are receiving topiramate are more or less likely than those receiving placebo to have at least a 50% reduction in migraine frequency or headache days, and this is also the case for reduction in migraine-related disability. [19] [20] [21] [22] Children who receive propranolol are possibly more likely than those who receive placebo to have more than a 50% reduction in headache frequency. 24, 38 Patients receiving amitriptyline combined with CBT as compared with those treated with amitriptyline who receive headache education are more likely to experience a decreased headache frequency and have more than a 50% reduction in headache frequency and are probably more likely to have decreased migraine-associated disability. 29 There is insufficient evidence to judge the independent effectiveness of amitriptyline on migraine prevention in children and adolescents. 20 A Food and Drug Administration (FDA) black box warning regarding risk of suicidal thoughts and behavior with amitriptyline use especially in children, adolescents, and young adults is in effect at the time of this guideline. It is possible that CBT alone is effective in migraine prevention, 10 and individual barriers to access may exist. 12 There is insufficient evidence to evaluate the effects of flunarizine, 25 nimodipine, 27 valproate, 23 and onabotulinumtoxinA 28 for use in migraine prevention in children and adolescents. Although there is evidence that cinnarizine 26 is probably more effective than placebo for migraine prevention, this medication is not available in the United States or Canada.
Statement 3a
Clinicians should inform patients and caregivers that in clinical trials of preventive treatments for pediatric migraine, many children and adolescents who received placebo improved and the majority of preventive medications were not superior to placebo (Level B).
Statement 3b
Acknowledging the limitations of currently available evidence, clinicians should engage in shared decision-making regarding the use of short-term treatment trials (a minimum of 2 months) for those who could benefit from preventive treatment (Level B).
Statement 3c
Clinicians should discuss the evidence for amitriptyline combined with CBT for migraine prevention, inform patients of the potential side effects of amitriptyline including risk of suicide, and work with families to identify providers who can offer this type of treatment 12 (Level B).
Statement 3d
Clinicians should discuss the evidence for topiramate for migraine prevention in children and adolescents and its side effects in this population (Level B).
Statement 3e
Clinicians should discuss the evidence for propranolol for migraine prevention and its side effects in children and adolescents (Level B).
Counseling for patients of childbearing potential Recommendation 4 rationale
Balancing benefit and risk is important when deciding among available medical treatments. Topiramate and valproate have well-demonstrated teratogenic effects, especially when used in polytherapy. [39] [40] [41] [42] Valproate use during pregnancy is also associated with developmental disorders in offspring. 43, 44 An FDA black box warning regarding fetal risk from valproate use exists as of the time of this guideline. Topiramate at a daily dose of 200 mg or less does not interact with oral combined hormonal contraceptives; however, at higher doses it can have drug interactions that decrease their effectiveness. 45 The risk of major congenital malformation in offspring of women with epilepsy taking anticonvulsants is possibly decreased by folic acid supplementation. 46 
Statement 4a
Clinicians must consider the teratogenic effect of topiramate and valproate in their choice of migraine prevention therapy recommendations to patients of childbearing potential (Level A).
Statement 4b
Clinicians who offer topiramate or valproate for migraine prevention to patients of childbearing potential must counsel these patients about potential effects on fetal/childhood development (Level A).
Statement 4c
Clinicians who prescribe topiramate for migraine prevention to patients of childbearing potential must counsel these patients about the potential of this medication to decrease the efficacy of oral combined hormonal contraceptives, particularly at doses over 200 mg daily (Level A).
Statement 4d
Clinicians who prescribe topiramate or valproate for migraine prevention to patients of childbearing potential should counsel patients to discuss optimal contraception methods with their health care provider during treatment (Level B).
Statement 4e
Clinicians must recommend daily folic acid supplementation to patients of childbearing potential who take topiramate or valproate (Level A).
Monitoring and stopping medication Recommendation 5 rationale
Migraine is a chronic disorder with spontaneous remissions and relapses. Clinical trials follow patients for limited periods of time. Patients and families often inquire about the duration of treatment. There is little information about when preventive treatment should be stopped, and the risk of relapse after discontinuation varies.
Statement 5a
Clinicians must periodically monitor medication effectiveness and adverse events when prescribing migraine preventive treatments (Level A).
Statement 5b
Clinicians should counsel patients and families about risks and benefits of stopping preventive medication once good migraine control is established (Level B).
Mental illness in children and adolescents with migraine Recommendation 6 rationale
Several studies have been performed, with inconsistent results, that evaluated the relationship between mental illness and migraine in children. A recent systematic review of prospective or retrospective longitudinal cohort studies in children examined factors associated with the onset and course of recurrent headache in children and adolescents, with recurrent headache defined as headaches occurring at least once per month. This review found high-quality evidence suggesting that children with negative emotional states, manifesting through anxiety, depression, or mental distress, are not at greater risk of developing recurrent headache; however, it found moderate-quality evidence that suggested the presence of comorbid negative emotional states in children with headache is associated with an increased risk of headache persistence in those who already experience recurrent headaches. 30 
Statement 6a
Children and adolescents with migraine should be screened for mood and anxiety disorders because of the increased risk of headache persistence (Level B).
Statement 6b
In children and adolescents with migraine who have comorbid mood and anxiety disorders, clinicians should discuss management options for these disorders (Level B).
Putting the evidence into a clinical context
The goal of preventive treatment is to reduce headache frequency and headache-related disability. Achieving clinically meaningful improvements should be the standard for assessing the effect of a given treatment. Involving patients and parents helps ensure that providers understand what clinically meaningful outcomes are as well as assists with treatment adherence and respects patient preferences. The choice of treatment can be guided by the presence of comorbidities (e.g., topiramate use in patients with epilepsy or the use of drugs that either decrease or increase appetite in patients with weight-related morbidity). Although topiramate is the only FDA-approved medication for migraine prevention (in children and adolescents aged 12-17 years), the current evidence base raises some doubts about whether this treatment achieves clinically meaningful outcomes beyond those obtained by placebo. There is insufficient evidence to confidently recommend this as a known efficacious preventive intervention. Some treatments with proven efficacy in adults, such as valproate for episodic migraine prevention and ona-botulinumtoxinA for chronic migraine, have not shown the same efficacy in children and adolescents, and a higher pediatric placebo response rate is observed. 47, 48 Analysis of placebo response rates across pediatric migraine trials show that trial designs associated with a lower placebo response rate included crossover design trials, single-center studies, and small sample size, with age and sex not predictive of placebo response rates. 49 The more rigorous trials have demonstrated a robust placebo response, and this response likely has a biological basis that can be potentially explored in clinical practice. 50 
Suggestions for future research
Improved classification of pediatric migraine and reliable measures of outcome and disability have improved our recognition and understanding of childhood migraine and enabled more robust clinical studies. However, variation in endpoints used in trials complicates assessment and comparison of potential benefit. The presence of high placebo response rates in pediatric migraine demonstrates that children respond to treatment of their headache but makes identifying a therapeutic response from pharmaceutical treatments more challenging. To account for this effect, unique study designs should be taken into consideration when planning trials. New therapeutics (drugs, devices, behavioral treatments) and further well-designed studies are needed. Specifically, the efficacy of and access to the use of CBT alone needs to be informed by future well-designed randomized controlled trials. Mechanistic studies that examine mediators of improvement when a patient with migraine receives a preventive intervention or placebo could be critical in understanding how and why children with headaches get better. This type of science might also suggest innovations related to new approaches to preventive therapies.
More evidence about the benefits of behavioral changes on reducing migraine burden, in particular compared with pharmacologic prevention, would help guide treatment recommendation. Factors that contribute to headache occurrence and persistence such as biologic and psychologic factors, including mood disorders, need to be investigated to identify pathophysiologic pathways and biomarkers. This identification can then be used to guide the development of new treatments and inform patients and families of their effect on outcome.
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